Published July 10, 2012 | Version v1
Journal article

Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases

  • 1. Radiation Oncology, Medical School Hannover, Hannover (Germany)
  • 2. Radiation Oncology, University of Frankfurt/Main, Frankfurt/Main (Germany)
  • 3. Radiation Oncology, TU München, München (Germany)
  • 4. Radiation Oncology, University of Ulm, Ulm (Germany)
  • 5. Radiation Oncology, University of Regensburg, Regensburg (Germany)
  • 6. Radiation Oncology, Hospital Traunstein, Traunstein (Germany)
  • 7. Radiation Oncology, Hospital Düren, Düren (Germany)
  • 8. Radiation Oncology, LMU München, München (Germany)
  • 9. Radiation Oncology, Martin Luther University, Halle/Saale (Germany)
  • 10. Radiation Oncology, Hospital Landshut, Landshut (Germany)
  • 11. Radiation Oncology, Hospital Salzburg, Salzburg (Austria)
  • 12. Radiation Oncology, University of Würzburg, Würzburg (Germany)
  • 13. Radiation Oncology, Martin Luther University Halle-Wittenberg, Halle/Saale (Germany)
  • 14. Radiation Oncology, St.-Josef-Hospital Gelsenkirchen-Horst, Gelsenkirchen (Germany)
  • 15. Radiation Oncology Radiation Oncology, Hospital Krems, Krems (Austria)
  • 16. Radiation Oncology, University of Münster, Münster (Germany)

Description

Recently published results of quality of life (QoL) studies indicated different outcomes of palliative radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might provide prognostic information. From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14 centers in Germany and Austria. Most patients (82 %) received whole-brain radiotherapy. QoL was measured with the EORTC-QLQ-C15-PAL and brain module BN20 before the start of radiotherapy and after 3 months. At 3 months, 88/142 (62 %) survived. Nine patients were not able to be followed up. 62 patients (70.5 % of 3-month survivors) completed the second set of questionnaires. Three months after the start of radiotherapy QoL deteriorated significantly in the areas of global QoL, physical function, fatigue, nausea, pain, appetite loss, hair loss, drowsiness, motor dysfunction, communication deficit and weakness of legs. Although the use of corticosteroid at 3 months could be reduced compared to pre-treatment (63 % vs. 37 %), the score for headaches remained stable. Initial QoL at the start of treatment was better in those alive than in those deceased at 3 months, significantly for physical function, motor dysfunction and the symptom scales fatigue, pain, appetite loss and weakness of legs. In a multivariate model, lower Karnofsky performance score, higher age and higher pain ratings before radiotherapy were prognostic of 3-month survival. Moderate deterioration in several QoL domains was predominantly observed three months after start of palliative radiotherapy for brain metastases. Future studies will need to address the individual subjective benefit or burden from such treatment. Baseline QoL scores before palliative radiotherapy for brain metastases may contain prognostic information

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-12-283; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434068

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
12
Journal Page Range
p. 283
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46102861
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
AUSTRIA; BRAIN; FEDERAL REPUBLIC OF GERMANY; HAIR; LEGS; METASTASES; NAUSEA; PAIN; PATIENTS; PERFORMANCE; RADIOTHERAPY; STANDARD OF LIVING
Descriptors DEC
BODY; CENTRAL NERVOUS SYSTEM; DEVELOPED COUNTRIES; EUROPE; LIMBS; MEDICINE; NERVOUS SYSTEM; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; SKIN; SYMPTOMS; THERAPY; WESTERN EUROPE

Optional Information

Copyright
Copyright (c)2012 Steinmann et al.
Notes
PMCID: PMC3434068; PUBLISHER-ID: 1471-2407-12-283; PMID: 22780988; OAI: oai:pubmedcentral.nih.gov:3434068; licensee BioMed Central Ltd.